Behind the Innovation: A Look at Jiuzhou Biology’s Stem Cell R&D Excellence

In the rapidly evolving landscape of biotechnology, few fields hold as much promise as stem cell research. From regenerative medicine to innovative skincare, the applications of stem cell technology are transforming industries at an unprecedented pace. At the forefront of this revolution stands Jiuzhou Biology — a leading stem cell R&D and production institution that has positioned itself as a powerhouse in China’s cell-based biotechnology sector.

As Yanyuan Bio‘s core partner in sourcing premium, clinically validated stem cell formulations, Jiuzhou Biology represents the gold standard in quality, innovation, and scientific rigor. In this article, we take an exclusive look behind the scenes at the R&D excellence that drives Jiuzhou Biology’s industry leadership.

Building a Complete Cell Gene Industry Platform

Founded in September 2006 and headquartered in the Xi‘an High-tech Zone, Shaanxi Jiuzhou Biomedical Technology Group Co., Ltd. (Jiuzhou Group) has grown into one of China’s earliest and most comprehensive stem cell research and development enterprises. With a total investment of RMB 450 million across its 62-acre industrial park, which spans 33,000 square meters, the company has established a fully integrated cell gene industry ecosystem — from cell collection, testing, and production to clinical research applications.

Central to its operations is the “One Park, One Chain, One Center” industrial structure, which has been recognized as a strategic pillar in Shaanxi Province‘s 14th Five-Year Plan and beyond.-1 The Shaanxi Jiuzhou Stem Cell Science and Technology Industrial Park houses 16 technology innovation research institutions, including the Shaanxi Provincial Stem Cell Application Engineering Research Center, the Shaanxi Provincial Cell Tissue Bank, the Western Cell Quality Testing and Standardization Research Center, an academician expert workstation, and a postdoctoral research sub-station, as well as the Institute of Regenerative Medicine, the Institute of Cell Therapy, and the Translational Medicine Center. This concentration of resources has transformed the park into a cluster for cellular gene medical services and a new engine for global innovations in life and health industries.

At the core of the ecosystem is a fully integrated cell gene industry chain — comprising a stem cell resource bank, a stem cell clinical research functional platform, a stem cell production center, a stem cell quality testing service platform, a genetic testing diagnostic platform, a medical service platform, and comprehensive health management technologies. Supported by an academician workstation and a team of over 50 renowned scientists and technical professionals, Jiuzhou has built a domestic-leading cell technology R&D platform, an independent cell and molecular gene laboratory, and a GMP-compliant cell laboratory with Class 10,000 cleanliness standards and world-class specialized equipment. This infrastructure enables foundational and applied research in the in vitro isolation, culture, expansion, induction, differentiation, and identification of stem cells, various immune cells, and adult stem cells, while providing safe and effective stem cell technologies for the treatment of major clinical diseases.

Pioneering iPSC Technology: The Next Frontier in Regenerative Medicine

A major milestone in Jiuzhou’s recent history came on March 28, 2026, with the launch of the “Jiuzhou Life Ark iPSC Project” in Xi‘an — a strategic initiative to fill a critical gap in the Western region’s high-end stem cell storage landscape.

Induced pluripotent stem cells — or iPSCs — represent one of the most advanced frontiers in cell therapy today. By reprogramming terminally differentiated somatic cells into a pluripotent state through the introduction of specific transcription factors, iPSCs can be directed to differentiate into virtually any cell type found in the human body. As noted by Gao Shaorong, an academician of the Chinese Academy of Sciences, “Compared to traditional stem cell technologies, iPSC technology completely circumvents the ethical controversies associated with embryonic stem cell research, while enabling individualized cell preparation and significantly reducing the risk of immune rejection in clinical applications.” This dual advantage positions iPSCs as a transformative force in regenerative medicine — a key scientific achievement representing the shift from “disease treatment” to “health intervention” in the quest for human well-being.

The project is expected to standardize iPSC cell storage protocols across Shaanxi, accelerate clinical translation, and support broader applications in public health management. Niu Suqin, Chairman of Shaanxi Jiuzhou Biomedical Technology Group, emphasized that the company is committed to continuously advancing iPSC technology into therapeutic areas such as Parkinson’s disease, spinal cord injury, and diabetes, while helping Shaanxi further complete its industrial, supply, and innovation chains. As a “chain master” enterprise in Shaanxi’s biomedical industry, Jiuzhou has already established China’s first full-industry cell gene transformation platform.

Translating Regenerative Science into Skincare Excellence

The transformative potential of stem cell innovation extends far beyond clinical medicine — and Jiuzhou has been instrumental in applying its discoveries to the skincare industry. In 2019, the company announced the launch of the country’s first cell exosome-based cosmetic skincare product. Leveraging targeted cellular signaling mechanisms, the product provides the substances needed for skin growth, improvement, and repair, offering a highly targeted approach to addressing issues such as rough skin and loss of firmness.- To date, the company has developed over 40 series products and more than 10 individual products, underscoring the scale and momentum of its efforts to commercialize advanced regenerative research.-

Xi’an Jiuzhou Regenerative Medicine Group Co., Ltd., a high-tech enterprise under the Jiuzhou umbrella, has further specialized in the application of exosome technology in medical aesthetics, skin repair, and health management. As a “chain master” enterprise in the biomedical industry chain and a provincial-level listed enterprise candidate, the group participated in drafting the industry group standard titled “Technical Requirements for the Application of Stem Cell Exosomes in Skin Anti-Aging.” Under the leadership of Chairman Xiang Ying, the group has built biotechnology skincare brands such as “Jimi” and “Mijiyin,” as well as the “Rejuvenation” series of facial rejuvenation solutions. With a dual focus on technology-driven skincare and regenerative aesthetic medicine, the group sits at the center of an integrated gene detection, cell storage, and precision health ecosystem.

In a landmark breakthrough announced in early 2026, the group‘s self-developed exosome raw materials successfully passed INCI (International Nomenclature of Cosmetic Ingredients) under number 40181. Combined with the previously achieved FDA DMF Type II drug master file (number 043407), this dual qualification — widely regarded as “two green cards” to the global market — represents both a powerful validation of the company’s R&D capabilities and quality systems and a critical enabler of global expansion. INCI is recognized in more than 70 countries and regions worldwide, including the U.S., China, the European Union, and Japan, and serves as an internationally accepted identification standard for cosmetic ingredients. The FDA DMF, for its part, confirms that the group‘s exosome raw materials — from quality systems to manufacturing processes to data documentation — have met the rigorous international standards for pharmaceutical raw materials. The dual registration means Jiuzhou can now serve both pharmaceutical and cosmetics markets globally, opening new avenues for industrial applications in new drug R&D, health management, and functional skincare. 

The clinical implications of exosome technology are equally far-reaching. According to recent reports, studies have shown that exosomes can significantly improve skin wrinkle depth and elasticity while promoting collagen regeneration. In the respiratory arena, inhaled exosomes delivered by nebulization have been shown to improve lung function in asthma and COPD patients and relieve airway obstruction; in neurology, intranasal administration bypasses the blood-brain barrier, with research published in Small demonstrating new exosome-based intervention strategies for Parkinson’s disease. Meanwhile, the “EXO 001 targeted exosome platform” launched by the hospital affiliated with China Medical University has achieved significant suppression of multiple solid tumors in animal models, while clinical explorations are underway in areas such as neuropathic pain and immuno-oncology. With an increasing number of institutions launching clinical trials of exosomes in fields ranging from anti-aging and respiratory medicine to neurology and oncology, the technology is rapidly moving from the laboratory to real-world application.

Why Jiuzhou‘s R&D Excellence Matters for Global Partners

For Yanyuan Bio and global B2B partners, Jiuzhou’s capabilities translate directly into market-ready advantages: clinically validated efficacy, production excellence, compliance with international standards, and an unbroken chain of quality oversight from molecular research to finished formulation.

Backed by a rigorous quality system, full-chain traceability, and a track record of translating complex biological science into commercially viable products, Jiuzhou has established itself as a trusted and scalable partner for brands seeking to enter the rapidly expanding global stem cell skincare market.

Through Yanyuan Bio’s exclusive distribution and brand operation partnership, international clients can now access Jiuzhou‘s premium clinical-grade stem cell formulations — from private label solutions to custom-developed brand programs — and enter global markets with the confidence that comes from world-class science, manufacturing, and regulatory compliance.